Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jianxin Capsule is a Traditional Chinese Medicine (TCM) formulation developed by Rugao Hospital of Traditional Chinese Medicine for the treatment of cardiac autonomic neuropathy (CAN) in patients with type 2 diabetes. The therapeutic mechanism involves the upregulation of the Nuclear factor erythroid 2-related factor 2 (Nrf2)/Antioxidant Response Element (ARE) signaling pathway. By activating this pathway, the drug aims to improve endogenous antioxidant defenses and mitigate oxidative stress-induced damage to the autonomic nervous system in diabetic patients. It is currently being evaluated in clinical trials for its efficacy and safety in this patient population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jianxin Capsule.